BBIO BridgeBio Pharma
- 28.685
- +0.185+0.65%
BridgeBio Pharma News
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today
BridgeBio Pharma Initiated at Outperform by Evercore ISI Group
BridgeBio Pharma Initiated at Outperform by Evercore ISI Group
BridgeBio Pharma (BBIO.US) was first covered by Evercore ISI Group, which gave it an superior market rating and a target price of $50.00.
BridgeBio Pharma (BBIO.US) was first covered by Evercore ISI Group, which gave it an superior market rating and a target price of $50.00.
Evercore ISI Group Initiates Coverage On BridgeBio Pharma With Outperform Rating, Announces Price Target of $50
Evercore ISI Group analyst Cory Kasimov initiates coverage on BridgeBio Pharma with a Outperform rating and announces Price Target of $50.
BridgeBio Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 74.46% Evercore ISI Group → $50 Initiates Coverage On → Outperform 03/20/2024 57.01% JP Morgan
Buy Rating on BridgeBio Pharma: Enhanced Market Prospects From Acoramidis Efficacy and Mortality Benefit
BridgeBio Pharma Presents Additional Data and Analyses From Its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis
BridgeBio Pharma Presents Additional Data and Analyses From Its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy, Including That Acoramidis Treatment Significantly Reduced All-Cause
Buy Rating Affirmed for BridgeBio Pharma on Strong Clinical Data for Acoramidis
What You Need To Know About The BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analyst Downgrade Today
BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Shares May Have Run Too Fast Too Soon
With a price-to-sales (or "P/S") ratio of 23.7x BridgeBio Pharma, Inc. (NASDAQ:BBIO) may be sending very bearish signals at the moment, given that almost half of all the Biotechs companies in the Unit
Buy Rating Affirmed: BridgeBio Pharma's Growth Trajectory Bolstered by Strong Pipeline and Strategic Initiatives
BridgeBio Pharma (BBIO.US): The 2024 Q1 financial report achieved revenue of US$211.1 million, with a previous value of US$1,826 million and an expected value of US$14.03 million; earnings per share were -0.20 dollars, the previous value was -0.92 dollars
BridgeBio Pharma (BBIO.US): The 2024 Q1 financial report achieved revenue of US$211.1 million, with a previous value of US$1,826 million and an expected value of US$14.03 million; earnings per share were -0.20 dollars, the previous value was -0.92 dollars, and the expected value was -0.89 dollars.
BridgeBio Pharma Shares Decline After Q1 Financial Results
BridgeBio Pharma's (BBIO) shares were slightly down in recent Thursday trading after the company reported its Q1 financial results. The company reported a Q1 net loss of $0.20 per diluted share, compa
Earnings Flash (BBIO) BRIDGEBIO PHARMA Posts Q1 Revenue $211.1M
07:32 AM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (BBIO) BRIDGEBIO PHARMA Posts Q1 Revenue $211.1M
BridgeBio Pharma 1Q Loss $36.2M >BBIO
BridgeBio Pharma 1Q Loss $36.2M >BBIO
Press Release: BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update - Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patien
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), Aurinia Pharmaceuticals (AUPH) and 908 Devices (MASS)
BridgeBio Launches BridgeBio Oncology Therapeutics (BBOT) With $200M of Private External Capital to Accelerate the Development of Its Novel Precision Oncology Pipeline
The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from affiliates of Deerfield Management, GV (Google Ventures), EcoR1 Capital, Wellington
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
- Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTRibute-CM Phase 3
Strong Buy Rating for BridgeBio Pharma Amid Positive HELIOS-B Study and Promising Infigratinib Developments
Analysis
Price Target
No Data
